<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Lemierre syndrome: Septic thrombophlebitis of the internal jugular vein
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Lemierre syndrome: Septic thrombophlebitis of the internal jugular vein
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Lemierre syndrome: Septic thrombophlebitis of the internal jugular vein
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Denis Spelman, MBBS, FRACP, FRCPA, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel J Sexton, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Milana Bogorodskaya, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2955814477">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lemierre syndrome refers to septic thrombophlebitis of the internal jugular vein (IJV). The condition typically begins with oropharyngeal infection and frequently involves inflammation within the wall of the vein, infected thrombus within the lumen, surrounding soft tissue inflammation, persistent bacteremia, and septic emboli. Other terms for Lemierre syndrome include postanginal sepsis and necrobacillosis [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p>
         There is no standardized definition of Lemierre syndrome; different criteria have been used in different series [
         <a href="#rid3">
          3
         </a>
         ]. Some series include only cases with the oropharynx as source of infection, while others allow other sources. Some series include only cases due to
         <em>
          Fusobacterium
         </em>
         species, while others allow other bacteria. Some series include only cases with evidence of septic emboli; other series include cases with positive blood cultures and evidence of septic emboli, even in the absence of IJV thrombosis.
        </p>
        <p>
         No systematic study of the pathophysiology, management, and outcome of Lemierre syndrome has been performed as this remains a sporadic and relatively rare condition.
        </p>
        <p class="headingAnchor" id="H2503996155">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lemierre syndrome is a rare disease; it occurs most commonly in otherwise healthy young adults [
         <a href="#rid4">
          4-6
         </a>
         ]. In a Danish study from 1998 to 2001, the annual incidence among individuals age 14 to 24, was 14.4 cases per million people; the incidence in the population was 3.6 cases per million people [
         <a href="#rid4">
          4
         </a>
         ]. Some studies suggest Lemierre syndrome might occur more often in men [
         <a href="#rid7">
          7,8
         </a>
         ]. Lemierre syndrome has also been described following solid organ transplantation [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2153246942">
         <span class="h1">
          MICROBIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lemierre syndrome is usually caused by members of the normal oropharyngeal flora [
         <a href="#rid10">
          10
         </a>
         ]. The most common pathogen is the anaerobe
         <em>
          Fusobacterium necrophorum
         </em>
         ; this pathogen has been isolated in healthy individuals as well as those with jugular vein suppurative thrombophlebitis and tonsillitis [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         <em>
          F. necrophorum
         </em>
         is an anaerobic nonmotile, filamentous,
         <em>
         </em>
         non-spore forming gram-negative bacillus. It has unique pleomorphic morphology compared with other fusobacteria, with filaments, short rods, and coccoid appearance on Gram stain [
         <a href="#rid12">
          12
         </a>
         ]. It may take ≥5 days for
         <em>
          F. necrophorum
         </em>
         to grow in culture.
        </p>
        <p>
         Other pathogens include other
         <em>
          Fusobacterium
         </em>
         species (eg,
         <em>
          Fusobacterium nucleatum
         </em>
         ) [
         <a href="#rid10">
          10
         </a>
         ] and other organisms such as Enterobacteriaceae [
         <a href="#rid13">
          13
         </a>
         ],
         <em>
          Eikenella corrodens
         </em>
         [
         <a href="#rid14">
          14
         </a>
         ],
         <em>
          Porphyromonas asaccharolytica
         </em>
         [
         <a href="#rid15">
          15
         </a>
         ],
         <em>
          Bacteroides
         </em>
         [
         <a href="#rid16">
          16
         </a>
         ], streptococci including
         <em>
          Streptococcus pyogenes
         </em>
         and
         <em>
          Streptococcus anginosus
         </em>
         [
         <a href="#rid17">
          17,18
         </a>
         ]. Rare cases due to
         <em>
          Staphylococcus aureus
         </em>
         , including methicillin-resistant
         <em>
          S. aureus
         </em>
         , have been described [
         <a href="#rid19">
          19-24
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1644776371">
         <span class="h1">
          PATHOGENESIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most cases of Lemierre syndrome, primary infection consists of pharyngitis affecting the palatine tonsils or peritonsillar tissue [
         <a href="#rid25">
          25
         </a>
         ]. Less common primary sources of infection include odontogenic infection, mastoiditis, otitis media, sinusitis, and parotitis [
         <a href="#rid5">
          5,26
         </a>
         ].
        </p>
        <p>
         Primary infection is followed by local invasion to the pharyngeal space and IJV causing septic thrombophlebitis, with an interval of one to three weeks [
         <a href="#rid1">
          1
         </a>
         ]. One case has been described following blunt trauma to the cervical region [
         <a href="#rid19">
          19
         </a>
         ]. The internal carotid artery, also located within the carotid sheath (
         <a class="graphic graphic_figure graphicRef67251" href="/z/d/graphic/67251.html" rel="external">
          figure 1
         </a>
         ), can also be inflamed [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
         How
         <em>
          F. necrophorum
         </em>
         causes septic thrombophlebitis is not known. Possible mechanisms include hematogenous spread via the tonsillar vein, peritonsillar invasion, or spread to the adjacent lateral pharyngeal space via the lymphatics (
         <a class="graphic graphic_figure graphicRef67251" href="/z/d/graphic/67251.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ]. Alternatively, alteration of the pharyngeal mucosa in the context of primary bacterial or viral infection may facilitate local invasion of
         <em>
          F necrophorum
         </em>
         , with direct extension through fascial planes of the neck to the IJV [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         Several reports have described Lemierre syndrome due to
         <em>
          F necrophorum
         </em>
         following Epstein-Barr virus infection; the mechanism is uncertain [
         <a href="#rid3">
          3,28
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3785206513">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H759643602">
         <span class="h2">
          Symptoms and signs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lemierre syndrome is frequently preceded by pharyngitis, usually in association with tonsil or peritonsillar involvement. Other antecedent conditions include mastoiditis, otitis, dental infections, pharyngeal abscesses, or infectious mononucleosis [
         <a href="#rid16">
          16
         </a>
         ]. The interval between antecedent infection and onset of IJV thrombophlebitis is usually one to three weeks [
         <a href="#rid10">
          10,16
         </a>
         ].
        </p>
        <p>
         Clinical manifestations may include fever (&gt;39°C), rigors, exudative tonsillitis, sore throat, dysphagia, trismus, unilateral neck pain, and tenderness [
         <a href="#rid16">
          16
         </a>
         ]. Respiratory symptoms (reflecting complicating septic pulmonary emboli) may include dyspnea, pleurisy, and/or hemoptysis; these may be present at the time of initial presentation and/or may develop subsequently (see
         <a class="local">
          'Complications'
         </a>
         below). Signs of IJV thrombosis include tenderness, swelling, and/or induration over the neck, over the angle of the jaw, or along the sternocleidomastoid muscle [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Physical examination of the oropharynx may demonstrate tonsils that are exudative, hyperemic, ulcerated, or normal; notable findings may have resolved by the time septic thrombophlebitis or metastatic complications occur [
         <a href="#rid10">
          10,16
         </a>
         ]. Careful examination of the neck is important because neck swelling can be mistaken for cervical lymph nodes rather than IJV thrombosis; however, a thrombosed IJV is rarely palpable and local signs can be absent. In one review including 109 cases, 47 percent of patients had no significant neck findings on presentation [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4255990126">
         <span class="h2">
          Complications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary complications are common [
         <a href="#rid3">
          3
         </a>
         ]. Lung lesions commonly present as necrotic cavitary lesions due to septic pulmonary emboli; in two reports, this finding was observed in 97 percent of cases [
         <a href="#rid10">
          10,16
         </a>
         ]. Other forms of pulmonary involvement include infiltrates, pleural effusions or empyema, lung abscesses, pneumothoraces, and necrotizing mediastinitis [
         <a href="#rid25">
          25
         </a>
         ]. In one review including 39 patients with Lemierre syndrome, 51 percent had sterile pleural effusions and 41 percent had lung abscesses; among those with lung abscesses, 25 percent developed an empyema [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
         Hematogenous spread to other sites can occur, with or without septic shock [
         <a href="#rid16">
          16,30
         </a>
         ]. Bacteremia may be transient, so blood cultures may or may not be positive. In a review of 109 cases of Lemierre syndrome,
         <em>
          F. necrophorum
         </em>
         was isolated from clinical specimens (mostly blood cultures) in 82 percent of cases [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         After pulmonary involvement, the large joints are the second most common sites affected by septic embolization [
         <a href="#rid1">
          1
         </a>
         ]. In one case series including 40 patients, joint involvement (most commonly knees and hips) was observed in 26 percent of cases; findings ranged from sterile effusions to suppurative arthritis [
         <a href="#rid29">
          29
         </a>
         ]. In another review including 109 patients, joint involvement was observed in 16 percent of cases; the hips, shoulders, and knees were most commonly affected [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         Other less common presentations of metastatic disease include cutaneous lesions, soft tissue abscesses, pyomyositis, osteomyelitis, splenic and liver abscesses, renal abscesses, endocarditis, pericarditis, and arterial complications (eg, mycotic carotid pseudoaneurysm) [
         <a href="#rid16">
          16,30,31
         </a>
         ].
        </p>
        <p>
         Involvement of the central nervous system (CNS) has been described but is unusual [
         <a href="#rid1">
          1
         </a>
         ]. Reported CNS complications include meningitis, brain abscesses, subdural empyemas, epidural abscess, septic emboli, and strokes [
         <a href="#rid27">
          27
         </a>
         ]. Cerebral venous thrombosis has also been described; presumably such cases result from retrograde extension of IJV thrombosis.
        </p>
        <p class="headingAnchor" id="H3293158251">
         <span class="h1">
          EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lemierre syndrome should be suspected in young adults with recent pharyngitis who present with fever, a tender/swollen neck, and/or pulmonary manifestations such as septic emboli [
         <a href="#rid25">
          25
         </a>
         ].
        </p>
        <p>
         The diagnostic evaluation includes obtaining specimens for culture and radiographic imaging of the neck and chest. In addition, further evaluation for complications should be tailored to findings on history and physical examination.
        </p>
        <p class="headingAnchor" id="H4190849193">
         <span class="h2">
          Diagnosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of Lemierre syndrome may be established in the setting of radiographic imaging demonstrating IJV thrombus, together with culture data demonstrating
         <em>
          F. necrophorum
         </em>
         or other implicated pathogen. Organisms may be isolated from the throat, the blood, and from metastatic sites of infection. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
         In the absence of both of these criteria, a presumptive diagnosis may be made for patients with either definitive radiographic imaging findings or definitive culture results.
        </p>
        <p class="headingAnchor" id="H3509388366">
         <span class="h2">
          Obtaining cultures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The microbiologic diagnosis may be made based on blood culture or throat culture. For patients with metastatic sites of infection who undergo drainage, a microbiologic diagnosis may also be made based on culture of recovered material.
        </p>
        <p class="headingAnchor" id="H2054963878">
         <span class="h2">
          Radiographic imaging
         </span>
         <span class="headingEndMark">
          —
         </span>
         Computed tomography (CT) scan of the neck and chest with contrast allows evaluation of the IJV for filling defects or thrombus; it also facilitates evaluation for lung involvement such as pulmonary emboli and abscesses [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Ultrasonography of the neck is an alternative modality for detection of IJV thrombus; it may demonstrate an echogenic region within a dilated IJV or a complex mass of cystic and solid components [
         <a href="#rid10">
          10
         </a>
         ]. However, ultrasonography is less sensitive than CT and is less useful for evaluation of regions deep to the clavicle or mandible [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         Magnetic resonance imaging of the neck has been used for detection of IJV thrombosis, but experience with this modality for this indication is limited [
         <a href="#rid32">
          32
         </a>
         ]. PET scan use has rarely been reported in diagnosing Lemierre syndrome, identifying complications, and demonstrating the response to therapy [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H386916249">
         <span class="h2">
          Additional evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional evaluation for complications should be tailored to findings on history and physical examination. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
         As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with joint involvement should undergo evaluation for septic arthritis. (See
         <a class="medical medical_review" href="/z/d/html/7666.html" rel="external">
          "Septic arthritis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with headache, neurologic deficits, or meningeal signs should undergo head imaging (preferably magnetic resonance imaging) to evaluate for neurologic complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with abdominal pain or other localizing symptoms should undergo CT of the abdomen and pelvis to evaluate for sites of metastatic infection that may warrant localized drainage.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2276282316">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Right-sided endocarditis – Right-sided endocarditis should be suspected in patients with fever with or without respiratory symptoms (such as cough, chest pain, hemoptysis), in the setting of relevant risk factors (injection drug use, presence of an intravascular device). The diagnosis is established based on clinical manifestations, blood cultures (or other microbiologic data), and echocardiography. (See
         <a class="medical medical_review" href="/z/d/html/2149.html" rel="external">
          "Right-sided native valve infective endocarditis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Catheter-associated septic thrombophlebitis – Catheter-associated septic thrombophlebitis should be suspected in patients with catheter-related bloodstream infection and persistent bacteremia after 72 hours of appropriate therapy. Complications include septic pulmonary emboli and secondary pneumonia; these may also be presenting manifestations of the infection. The presence of venous thrombosis may be established via duplex ultrasonography; the microbiologic diagnosis may be based on blood culture. (See
         <a class="medical medical_review" href="/z/d/html/3813.html" rel="external">
          "Intravascular non-hemodialysis catheter-related infection: Clinical manifestations and diagnosis", section on 'Complications'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Malignancy – Bilateral internal jugular venous thrombosis has been associated with underlying malignancy; screening for malignancy should be considered in such cases [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7565.html" rel="external">
          "Screening for colorectal cancer: Strategies in patients at average risk"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7564.html" rel="external">
          "Screening for breast cancer: Strategies and recommendations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1177626253">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The principles of treatment include appropriate antibiotic therapy as well as consideration regarding the need for surgical intervention and anticoagulation.
        </p>
        <p class="headingAnchor" id="H909272923">
         <span class="h2">
          Antibiotics
         </span>
        </p>
        <p class="headingAnchor" id="H3320512269">
         <span class="h3">
          Empiric therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Empiric therapy for classic Lemierre syndrome (jugular vein suppurative thrombophlebitis with an oropharyngeal source) should target
         <em>
          F. necrophorum
         </em>
         and oral streptococci.
        </p>
        <p>
         The regimen should consist of an antibiotic regimen that is resistant to beta-lactamase, since
         <em>
          F. necrophorum
         </em>
         beta-lactamase production and treatment failure with penicillin has been reported [
         <a href="#rid10">
          10,35
         </a>
         ].
        </p>
        <p>
         Empiric antibiotic regimens include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          Piperacillin-tazobactam
         </a>
         (3.375 g intravenously [IV] every six hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A carbapenem such as
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         (500 mg IV every 6 hours) OR
         <a class="drug drug_general" data-topicid="9613" href="/z/d/drug information/9613.html" rel="external">
          meropenem
         </a>
         (1 g IV every 8 hours) OR
         <a class="drug drug_general" data-topicid="8675" href="/z/d/drug information/8675.html" rel="external">
          ertapenem
         </a>
         (1 g IV every 24 hours)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          Ceftriaxone
         </a>
         (2 g IV every 24 hours) plus
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (500 mg IV every 8 hours)
        </p>
        <p>
        </p>
        <p>
         We do not favor use of empiric
         <a class="drug drug_general" data-topicid="8745" href="/z/d/drug information/8745.html" rel="external">
          ampicillin-sulbactam
         </a>
         because resistance rates are higher than for
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         or carbapenems [
         <a href="#rid36">
          36,37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/482.html" rel="external">
          "Combination beta-lactamase inhibitors, carbapenems, and monobactams", section on 'Beta-lactamase inhibitor combinations'
         </a>
         .)
        </p>
        <p>
         For patients with hemodynamic instability or other findings suggestive of severe disease, or risk factors for methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection (
         <a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">
          table 1
         </a>
         ), we include
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for empiric coverage of MRSA (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         For patients with known or suspected central nervous system (CNS) involvement, a broad-spectrum regimen with favorable CNS penetration should be used, such as
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         ),
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g IV every 12 hours), and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (500 mg IV every 8 hours).
        </p>
        <p class="headingAnchor" id="H2734488417">
         <span class="h3">
          Tailoring therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibiotics should be tailored accordingly to culture and susceptibility data when available.
        </p>
        <p>
         If cultures grow
         <em>
          F. necrophorum,
         </em>
         the antibiotic regimen can be narrowed to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         monotherapy once there are signs of clinical improvement. Antimicrobial resistance among
         <em>
          F. necrophorum
         </em>
         is rare. In one review including 100
         <em>
          F. necrophorum
         </em>
         isolates, all were susceptible to metronidazole,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8553" href="/z/d/drug information/8553.html" rel="external">
          imipenem
         </a>
         ,
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9223" href="/z/d/drug information/9223.html" rel="external">
          cefoxitin
         </a>
         ; penicillin resistance was observed in 2 percent of strains [
         <a href="#rid7">
          7
         </a>
         ]. However, other authors note that up to 10 percent of isolates are resistant to clindamycin [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
         The duration of antibiotic therapy should be guided by clinical circumstances. In general, we favor an antibiotic duration of at least four weeks, including at least two weeks of intravenous therapy [
         <a href="#rid4">
          4
         </a>
         ]. In the setting of complications (such as pulmonary abscesses, septic arthritis, etc), the duration of antibiotic therapy should be adjusted accordingly. (See related topics.)
        </p>
        <p>
         The clinical response to treatment may be slow, even with appropriate antimicrobial therapy. In two studies, the mean time to defervescence was eight to nine days [
         <a href="#rid39">
          39,40
         </a>
         ]. This may be because of limited antibiotic penetration into fibrin clot and/or necrotic abscesses [
         <a href="#rid12">
          12,41
         </a>
         ].
        </p>
        <p>
         In the setting of persistent bacteremia or clinical worsening despite appropriate antimicrobial therapy, our approach is as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform repeat computed tomography imaging to evaluate for extension of thrombus or other complications.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pursue formal antimicrobial susceptibility testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Add empiric
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (500 mg IV every 8 hours) if not already part of the antibiotic regimen, to optimize targeted anaerobic therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ensure patients with purulent fluid collections undergo drainage. (See
         <a class="local">
          'Interventional procedures'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluate indications for anticoagulation. (See
         <a class="local">
          'Anticoagulation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Once the infection has been controlled (based on clinical circumstances, including resolution of fever and completion of drainage or debridement if necessary), and two weeks of intravenous therapy have been completed, antibiotic therapy can be completed orally. Oral options for treatment of
         <em>
          F. necrophorum
         </em>
         infection include
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (500 mg orally three times daily), amoxicillin-clavulanic acid (875/125 mg orally twice daily), or
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         (450 mg orally three times daily).
        </p>
        <p class="headingAnchor" id="H3991652138">
         <span class="h2">
          Anticoagulation
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is uncertain whether anticoagulation may reduce propagation of thrombus or septic embolic events originating from IJV thrombosis; data are limited to case reports [
         <a href="#rid34">
          34,42
         </a>
         ].
        </p>
        <p>
         In general, we suggest not treating most patients with anticoagulation. We pursue anticoagulation in the setting of progression of thrombosis or continued fever or bacteremia after five to seven days of appropriate antimicrobial therapy (with drainage of purulent collections as appropriate), given potential concern for retrograde progression into the cavernous or other sinus.
        </p>
        <p>
         When anticoagulation is used, the optimal duration is uncertain. It is reasonable to discontinue anticoagulation once the patient has improved clinically and imaging suggests that thrombus extension has ceased. Anticoagulation for longer than six weeks may be appropriate for patients with embolic disease or underlying prothrombotic risk factors; we typically consult with a hematologist regarding the optimal duration.
        </p>
        <p>
         Thrombolytic therapy is an additional option when thrombosis progresses [
         <a href="#rid34">
          34
         </a>
         ], but there is minimal experience with this treatment in Lemierre syndrome and no conclusive evidence of efficacy.
        </p>
        <p class="headingAnchor" id="H1700666495">
         <span class="h2">
          Interventional procedures
         </span>
         <span class="headingEndMark">
          —
         </span>
         The need for interventional procedures should be guided by clinical circumstances. As examples, patients with purulent fluid collections should undergo drainage, patients with empyema should undergo chest tube drainage, and patients with necrotic tissue should undergo debridement [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         For patients with uncontrolled sepsis or ongoing septic emboli despite appropriate antibiotic therapy and anticoagulation, ligation or excision of the IJV has been described [
         <a href="#rid10">
          10,25,39,43
         </a>
         ]. This approach should be viewed as a last resort. In one review including more than 390 patients with Lemierre syndrome between 1990 and 2017, only 10 were treated with IJV ligation or excision [
         <a href="#rid43">
          43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1466539706">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Lemierre syndrome refers to septic thrombophlebitis of the internal jugular vein (IJV). It is a rare disease that occurs most commonly in otherwise healthy young adults. The condition typically begins with oropharyngeal infection and frequently involves inflammation within the wall of the vein, infected thrombus within the lumen, inflammation of surrounding soft tissues, persistent bacteremia, and septic emboli. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiology
         </strong>
         – Lemierre syndrome is usually caused by oropharyngeal flora; the most common pathogens are the anaerobe
         <em>
          Fusobacterium necrophorum
         </em>
         and oral streptococci. Rare cases due to
         <em>
          Staphylococcus aureus
         </em>
         have been described. (See
         <a class="local">
          'Microbiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical manifestations
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Symptoms and signs
         </strong>
         – Clinical manifestations may include fever, rigors, exudative tonsillitis, sore throat, dysphagia, trismus, unilateral neck pain, and tenderness. Signs of IJV thrombosis include tenderness, swelling, and/or induration over the neck, over the angle of the jaw, or along the sternocleidomastoid muscle. Physical examination of the oropharynx may demonstrate tonsils that are exudative, hyperemic, ulcerated, or normal; findings may have resolved by the time septic thrombophlebitis or metastatic complications occur. (See
         <a class="local">
          'Symptoms and signs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complications
         </strong>
         – Complications arise in the setting of hematogenous spread of infection. Pulmonary complications are common; symptoms including dyspnea, pleurisy, and/or hemoptysis are common. Lung lesions commonly present as necrotic cavitary lesions due to septic pulmonary emboli. The large joints are the second most commonly affected site of metastatic infection. Involvement of the central nervous system (CNS) has been described but is uncommon. Cerebral venous thrombosis has also been described; presumably such cases result from retrograde extension of IJV thrombosis. (See
         <a class="local">
          'Complications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Evaluation
         </strong>
         – Lemierre syndrome should be suspected in young adults with recent pharyngitis who present with fever, a tender/swollen neck, and/or pulmonary manifestations such as septic emboli. The diagnostic evaluation includes obtaining specimens for culture and radiographic imaging of the neck and chest. In addition, further evaluation for complications should be tailored to findings on history and physical examination. (See
         <a class="local">
          'Evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Management
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Antibiotic therapy
         </strong>
         – Empiric antibiotic therapy for classic Lemierre syndrome (jugular vein suppurative thrombophlebitis with an oropharyngeal source) should target
         <em>
          F. necrophorum
         </em>
         and oral streptococci using combination therapy. Antibiotics should be tailored accordingly to culture and susceptibility data when available.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         We suggest an antibiotic regimen that is resistant to beta-lactamase (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         );
         <em>
          F. necrophorum
         </em>
         beta-lactamase production and treatment failure with penicillin has been reported. Empiric antibiotic regimens include
         <a class="drug drug_general" data-topicid="9777" href="/z/d/drug information/9777.html" rel="external">
          piperacillin-tazobactam
         </a>
         , a carbapenem, or
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         plus
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         . (See
         <a class="local">
          'Empiric therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         For patients with hemodynamic instability or other findings suggestive of severe disease, or risk factors for methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA) infection (
         <a class="graphic graphic_table graphicRef53504" href="/z/d/graphic/53504.html" rel="external">
          table 1
         </a>
         ), we include
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         for empiric coverage of MRSA (
         <a class="graphic graphic_table graphicRef128911" href="/z/d/graphic/128911.html" rel="external">
          table 2
         </a>
         ). For patients with known or suspected CNS involvement, we use a broad-spectrum regimen with favorable CNS penetration such as vancomycin,
         <a class="drug drug_general" data-topicid="9229" href="/z/d/drug information/9229.html" rel="external">
          ceftriaxone
         </a>
         (2 g intravenously [IV] every 12 hours), and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (500 mg IV every 8 hours).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Duration
         </strong>
         – We suggest an antibiotic duration of at least four weeks, including at least two weeks of intravenous therapy (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In the setting of complications (such as pulmonary abscesses, septic arthritis, etc), the duration of antibiotic therapy should be adjusted accordingly. (See
         <a class="local">
          'Tailoring therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory disease
         </strong>
         – The clinical response to treatment may be slow, even with appropriate antimicrobial therapy. In the setting of persistent bacteremia or clinical worsening despite appropriate antimicrobial therapy, we perform repeat computed tomography imaging to evaluate for extension of thrombus or other complications. We also pursue formal antimicrobial susceptibility testing, add empiric
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         (if not already part of the antibiotic regimen) to optimize targeted anaerobic therapy, and ensure patients with purulent fluid collections undergo drainage. (See
         <a class="local">
          'Tailoring therapy'
         </a>
         above and
         <a class="local">
          'Interventional procedures'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Anticoagulation
         </strong>
         – We suggest not treating most patients with anticoagulation (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Exceptions include patients with evidence of progression of thrombosis or continued fever or bacteremia despite appropriate antibiotic therapy (See
         <a class="local">
          'Tailoring therapy'
         </a>
         above and
         <a class="local">
          'Interventional procedures'
         </a>
         above and
         <a class="local">
          'Anticoagulation'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kuppalli K, Livorsi D, Talati NJ, Osborn M. Lemierre's syndrome due to Fusobacterium necrophorum. Lancet Infect Dis 2012; 12:808.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riordan T, Wilson M. Lemierre's syndrome: more than a historical curiosa. Postgrad Med J 2004; 80:328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riordan T. Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome. Clin Microbiol Rev 2007; 20:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagelskjaer Kristensen L, Prag J. Lemierre's syndrome and other disseminated Fusobacterium necrophorum infections in Denmark: a prospective epidemiological and clinical survey. Eur J Clin Microbiol Infect Dis 2008; 27:779.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Armstrong AW, Spooner K, Sanders JW. Lemierre's Syndrome. Curr Infect Dis Rep 2000; 2:168.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baker CC, Petersen SR, Sheldon GF. Septic phlebitis: a neglected disease. Am J Surg 1979; 138:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brazier JS, Hall V, Yusuf E, Duerden BI. Fusobacterium necrophorum infections in England and Wales 1990-2000. J Med Microbiol 2002; 51:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagelskjaer LH, Prag J, Malczynski J, Kristensen JH. Incidence and clinical epidemiology of necrobacillosis, including Lemierre's syndrome, in Denmark 1990-1995. Eur J Clin Microbiol Infect Dis 1998; 17:561.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gomide LMES, Zarate Nissel MA, Weihermann V, et al. Septic Thrombophlebitis of the Internal Jugular Vein in an Immunocompromised Patient with Lemierre Syndrome: A Case Report. Transplant Proc 2022; 54:1388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Golpe R, Marín B, Alonso M. Lemierre's syndrome (necrobacillosis). Postgrad Med J 1999; 75:141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen A, Hagelskjaer Kristensen L, Prag J. Detection of Fusobacterium necrophorum subsp. funduliforme in tonsillitis in young adults by real-time PCR. Clin Microbiol Infect 2007; 13:695.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagelskjaer Kristensen L, Prag J. Human necrobacillosis, with emphasis on Lemierre's syndrome. Clin Infect Dis 2000; 31:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spaziante M, Giuliano S, Ceccarelli G, et al. Gram-negative septic thrombosis in critically ill patients: A retrospective case-control study. Int J Infect Dis 2020; 94:110.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Celikel TH, Muthuswamy PP. Septic pulmonary emboli secondary to internal jugular vein phlebitis (postanginal sepsis) caused by Eikenella corrodens. Am Rev Respir Dis 1984; 130:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morizono S, Enjoji M, Sonoda N, et al. Lemierre's syndrome: Porphyromonas asaccharolytica as a putative pathogen. Intern Med 2005; 44:350.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinave CP, Hardy GJ, Fardy PW. The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection. Medicine (Baltimore) 1989; 68:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anton E. Lemierre syndrome caused by Streptococcus pyogenes in an elderly man. Lancet Infect Dis 2007; 7:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Camacho-Cruz J, Preciado H, Beltrán N, et al. Lemierre's Syndrome Caused by Streptococcus anginosus Presenting as Postseptal Cellulitis in a Pediatric Patient. ORL J Otorhinolaryngol Relat Spec 2019; 81:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denesopolis JM, Medicherla Singh RC, Shah AR, et al. A unique case of Lemierre's syndrome status post blunt cervical trauma. Vascular 2020; 28:485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zamora Gonzalez RA, Sarria JC, Christians NA, Baliss M. Lemierre's Syndrome Due to Methicillin-Resistant Staphylococcus aureus. J Investig Med High Impact Case Rep 2019; 7:2324709619890967.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correia MS, Sadler C. Methicillin-Resistant Staphylococcus aureus Septic Internal Jugular Thrombophlebitis: Updates in the Etiology and Treatment of Lemierre's Syndrome. J Emerg Med 2019; 56:709.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kizhner V, Samara G, Panesar R, Krespi YP. Methicillin-resistant Staphylococcus aureus bacteraemia associated with Lemierre's syndrome: case report and literature review. J Laryngol Otol 2013; 127:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidambi TD, Lee C, Kohlwes RJ. MRSA-Associated Lemierre's Syndrome in an Intravenous Drug User. J Gen Intern Med 2015; 30:1886.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stauffer C, Josiah AF, Fortes M, et al. Lemierre syndrome secondary to community-acquired methicillin-resistant Staphylococcus aureus infection associated with cavernous sinus thromboses. J Emerg Med 2013; 44:e177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chirinos JA, Lichtstein DM, Garcia J, Tamariz LJ. The evolution of Lemierre syndrome: report of 2 cases and review of the literature. Medicine (Baltimore) 2002; 81:458.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olaf M, Duguet L. Mastoiditis with concomitant Lemierre's syndrome. Am J Emerg Med 2019; 37:1214.e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pleming W, Barco S, Voci D, et al. Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis. Hamostaseologie 2022; 42:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adams J, Capistrant T, Crossley K, et al. Fusobacterium necrophorum septicemia. JAMA 1983; 250:35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leugers CM, Clover R. Lemierre syndrome: postanginal sepsis. J Am Board Fam Pract 1995; 8:384.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pruitt BA Jr, McManus WF, Kim SH, Treat RC. Diagnosis and treatment of cannula-related intravenous sepsis in burn patients. Ann Surg 1980; 191:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bordet M, Long A, Tresson P. Mycotic Pseudoaneurysm of Carotid Artery as a Rare Complication of Lemierre Syndrome. Mayo Clin Proc 2021; 96:3178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auber AE, Mancuso PA. Lemierre syndrome: magnetic resonance imaging and computed tomographic appearance. Mil Med 2000; 165:638.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carandini T, Longari V, Mendogni P, et al. Utility of PET scan in diagnosis and monitoring descending necrotizing mediastinitis complicating Lemierre's syndrome. Intern Emerg Med 2018; 13:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Phua CK, Chadachan VM, Acharya R. Lemierre syndrome-should we anticoagulate? A case report and review of the literature. Int J Angiol 2013; 22:137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seidenfeld SM, Sutker WL, Luby JP. Fusobacterium necrophorum septicemia following oropharyngeal infection. JAMA 1982; 248:1348.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev 2013; 26:526.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Appelbaum PC, Spangler SK, Jacobs MR. Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers. Antimicrob Agents Chemother 1990; 34:1546.
          </a>
         </li>
         <li class="breakAll">
          Brook I. Antibiotic-resistant pathogens in ear, nose, and throat infections. In: Infections of the Ears, Nose, Throat, and Sinuses, Durand ML, Deschler DG (Eds), Springer International, Cham. Switzerland 2018. p.15.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moreno S, García Altozano J, Pinilla B, et al. Lemierre's disease: postanginal bacteremia and pulmonary involvement caused by Fusobacterium necrophorum. Rev Infect Dis 1989; 11:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lustig LR, Cusick BC, Cheung SW, Lee KC. Lemierre's syndrome: two cases of postanginal sepsis. Otolaryngol Head Neck Surg 1995; 112:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bergeron MG, Robert J, Beauchamp D. Pharmacodynamics of antibiotics in fibrin clots. J Antimicrob Chemother 1993; 31 Suppl D:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nygren D, Elf J, Torisson G, Holm K. Jugular Vein Thrombosis and Anticoagulation Therapy in Lemierre's Syndrome-A Post Hoc Observational and Population-Based Study of 82 Patients. Open Forum Infect Dis 2021; 8:ofaa585.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gore MR. Lemierre Syndrome: A Meta-analysis. Int Arch Otorhinolaryngol 2020; 24:e379.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 129255 Version 11.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22633566" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Lemierre's syndrome due to Fusobacterium necrophorum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15192164" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Lemierre's syndrome: more than a historical curiosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17934077" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Human infection with Fusobacterium necrophorum (Necrobacillosis), with a focus on Lemierre's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18330604" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Lemierre's syndrome and other disseminated Fusobacterium necrophorum infections in Denmark: a prospective epidemiological and clinical survey.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11095853" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Lemierre's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/464215" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Septic phlebitis: a neglected disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11871622" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fusobacterium necrophorum infections in England and Wales 1990-2000.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9796654" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Incidence and clinical epidemiology of necrobacillosis, including Lemierre's syndrome, in Denmark 1990-1995.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35688768" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Septic Thrombophlebitis of the Internal Jugular Vein in an Immunocompromised Patient with Lemierre Syndrome: A Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10448489" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Lemierre's syndrome (necrobacillosis).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403128" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Detection of Fusobacterium necrophorum subsp. funduliforme in tonsillitis in young adults by real-time PCR.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10987717" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Human necrobacillosis, with emphasis on Lemierre's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32126323" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Gram-negative septic thrombosis in critically ill patients: A retrospective case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6383158" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Septic pulmonary emboli secondary to internal jugular vein phlebitis (postanginal sepsis) caused by Eikenella corrodens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15897651" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Lemierre's syndrome: Porphyromonas asaccharolytica as a putative pathogen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2646510" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : The Lemierre syndrome: suppurative thrombophlebitis of the internal jugular vein secondary to oropharyngeal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17317605" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Lemierre syndrome caused by Streptococcus pyogenes in an elderly man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31315119" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Lemierre's Syndrome Caused by Streptococcus anginosus Presenting as Postseptal Cellulitis in a Pediatric Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32228176" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A unique case of Lemierre's syndrome status post blunt cervical trauma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31795752" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Lemierre's Syndrome Due to Methicillin-Resistant Staphylococcus aureus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31229258" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Methicillin-Resistant Staphylococcus aureus Septic Internal Jugular Thrombophlebitis: Updates in the Etiology and Treatment of Lemierre's Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23701713" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Methicillin-resistant Staphylococcus aureus bacteraemia associated with Lemierre's syndrome: case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25740463" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : MRSA-Associated Lemierre's Syndrome in an Intravenous Drug User.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22989693" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lemierre syndrome secondary to community-acquired methicillin-resistant Staphylococcus aureus infection associated with cavernous sinus thromboses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12441902" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The evolution of Lemierre syndrome: report of 2 cases and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30786966" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Mastoiditis with concomitant Lemierre's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35255510" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Cardiac and Cerebral Arterial Complications of Lemierre Syndrome: Results from a Systematic Review and Individual Patient Data Meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6854884" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Fusobacterium necrophorum septicemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7484226" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Lemierre syndrome: postanginal sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7369818" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Diagnosis and treatment of cannula-related intravenous sepsis in burn patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34863401" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mycotic Pseudoaneurysm of Carotid Artery as a Rare Complication of Lemierre Syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10957863" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Lemierre syndrome: magnetic resonance imaging and computed tomographic appearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28776174" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Utility of PET scan in diagnosis and monitoring descending necrotizing mediastinitis complicating Lemierre's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24436600" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lemierre syndrome-should we anticoagulate? A case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6955528" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Fusobacterium necrophorum septicemia following oropharyngeal infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23824372" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Antianaerobic antimicrobials: spectrum and susceptibility testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2221864" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2221864" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2649965" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Lemierre's disease: postanginal bacteremia and pulmonary involvement caused by Fusobacterium necrophorum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7777368" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Lemierre's syndrome: two cases of postanginal sepsis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8335514" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pharmacodynamics of antibiotics in fibrin clots.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33447643" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Jugular Vein Thrombosis and Anticoagulation Therapy in Lemierre's Syndrome-A Post Hoc Observational and Population-Based Study of 82 Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32754251" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Lemierre Syndrome: A Meta-analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
